Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration
- PDF / 580,390 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 3 Downloads / 181 Views
ORIGINAL RESEARCH
Ticagrelor Pharmacokinetics and Pharmacodynamics in Chinese Patients with STEMI and NSTEMI Without Opioid Administration Yinman Wang . Hongyi Wu . Yaolin Chen . Qibing Wang . Juying Qian
. Junbo Ge
Received: May 13, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: The pharmacodynamics (PD) and pharmacokinetics (PK) study of ticagrelor loading dose (LD) in Chinese patients with acute coronary syndrome (ACS) without opioid administration has never been investigated. Therefore, the aim of this study was to evaluate the antiplatelet effects and the PK parameters of ticagrelor in Chinese patients with ACS without opioid administration. Methods: A sample size of 30 eligible patients with ACS were enrolled in this study. Blood samples were obtained predose and 1, 2, 4, 8, and 12 h after 180 mg LD of ticagrelor. P2Y12 reactivity units (PRU) and plasma concentrations of ticagrelor and its two metabolites were measured. Yinman Wang, Hongyi Wu, and Yaolin Chen contributed equally to this work and should be considered co-first authors.
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12453809. Y. Wang H. Wu Q. Wang J. Qian (&) J. Ge Department of Cardiology, Zhongshan Hospital, Fudan University. Shanghai Institute of Cardiovascular Diseases, Shanghai, China e-mail: [email protected] Y. Chen Department of Cardiology, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, Fujian Province, China
Results: In total, 15 patients were admitted to ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) groups, respectively. For patients with NSTEMI, PRU declined significantly during the first 4 h and maintained a relatively stable antiplatelet effect from 4 to 12 h after LD. A similar trend was found in the STEMI group without significant differences of PRU in each designed time compared with patients with NSTEMI (P [ 0.05). Tmax of metabolite AR-C124910XX was 4 h after LD for both groups. There were no significant differences for drug concentration, Cmax, or AUC of ticagrelor and AR-C124910XX between patients with STEMI and NSTEMI (P [ 0.05). Conclusions: For Chinese patients with ACS, at least 4 h was needed to achieve an adequate antiplatelet effect for ticagrelor LD. There were no differences in PK or PD between Chinese patients with STEMI and NSTEMI. Clinical Trial Registration: ChiCTR1800014 764. Keywords: Acute coronary syndrome; Antiplatelet effect; Pharmacokinetics; Ticagrelor
Adv Ther
Key Summary Points Why carry out this study? The aim of this study was to evaluate the antiplatelet effects and the PK parameters of ticagrelor in Chinese patients with acute coronary syndrome (ACS) without opioid administration. We compared the pharmacokinetics and pharmacodynamics after ticagrelor loading dose in patients with different types of ACS without morphine effects or percutaneous coronary intervention interference. What was learned from the
Data Loading...
